Literature DB >> 25064318

Infectious diarrhea: an overview.

Brandon Dickinson1, Christina M Surawicz.   

Abstract

Diarrheal disease, which is most often caused by infectious pathogens, is a significant cause of morbidity and mortality worldwide, especially in children. This is particularly true in developing countries. Recent outbreaks of infectious diarrhea in developed countries, including the USA, are often attributed to food handling and distribution practices and highlight the need for continued vigilance in this area. Another common cause of infectious diarrhea, Clostridium difficile infection (CDI), has historically been associated with the use of antibiotics and exposure to a health-care setting but is now increasingly common in the community in persons who lack the typical risk factors. Recent scientific advances have also led to new and proposed new therapies for infectious diarrhea, including fecal microbiota transplant (FMT) for recurrent C. difficile infection (RCDI), probiotics for prevention of antibiotic-associated diarrhea (AAD) and CDI, and the use of zinc supplementation in the treatment of acute diarrhea in children. Other therapies that have been in use for decades, such as the oral rehydration solution (ORS), continue to be the targets of scientific advancement in an effort to improve delivery and efficacy. Finally, post-infectious irritable bowel syndrome (PI-IBS) is an increasingly recognized occurrence. Attempts to understand the mechanism behind this phenomenon are underway and may provide insight into potential treatment options.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25064318     DOI: 10.1007/s11894-014-0399-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  66 in total

1.  Scientific rationale for a change in the composition of oral rehydration solution.

Authors:  Christopher Duggan; Olivier Fontaine; Nathaniel F Pierce; Roger I Glass; Dilip Mahalanabis; Nur Haque Alam; Maharaj K Bhan; Mathuram Santosham
Journal:  JAMA       Date:  2004-06-02       Impact factor: 56.272

2.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

Review 3.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

4.  Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea.

Authors:  Lukas Buendgens; Jan Bruensing; Michael Matthes; Hanna Dückers; Tom Luedde; Christian Trautwein; Frank Tacke; Alexander Koch
Journal:  J Crit Care       Date:  2014-03-07       Impact factor: 3.425

5.  Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection.

Authors:  Eero Mattila; Raija Uusitalo-Seppälä; Maarit Wuorela; Laura Lehtola; Heimo Nurmi; Matti Ristikankare; Veikko Moilanen; Kimmo Salminen; Maaria Seppälä; Petri S Mattila; Veli-Jukka Anttila; Perttu Arkkila
Journal:  Gastroenterology       Date:  2011-12-07       Impact factor: 22.682

Review 6.  Zinc status and immune system relationship: a review.

Authors:  M J Salgueiro; M Zubillaga; A Lysionek; G Cremaschi; C G Goldman; R Caro; T De Paoli; A Hager; R Weill; J Boccio
Journal:  Biol Trace Elem Res       Date:  2000-09       Impact factor: 3.738

7.  Evaluation of oral rehydration solution by whole-gut perfusion in rats: effect of osmolarity, sodium concentration and resistant starch.

Authors:  Sandeep Subramanya; Balakrishnan S Ramakrishna; Henry J Binder; Michael J Farthing; Graeme P Young
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-11       Impact factor: 2.839

8.  Zinc inhibits cholera toxin-induced, but not Escherichia coli heat-stable enterotoxin-induced, ion secretion in human enterocytes.

Authors:  Roberto Berni Canani; Pia Cirillo; Vittoria Buccigrossi; Serena Ruotolo; Annalisa Passariello; Patrick De Luca; Francesco Porcaro; Giulio De Marco; Alfredo Guarino
Journal:  J Infect Dis       Date:  2005-02-22       Impact factor: 5.226

9.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.

Authors:  Daniel E Freedberg; Hojjat Salmasian; Carol Friedman; Julian A Abrams
Journal:  Am J Gastroenterol       Date:  2013-09-24       Impact factor: 10.864

10.  Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers.

Authors:  Lotta Krogius-Kurikka; Anna Lyra; Erja Malinen; Johannes Aarnikunnas; Jarno Tuimala; Lars Paulin; Harri Mäkivuokko; Kajsa Kajander; Airi Palva
Journal:  BMC Gastroenterol       Date:  2009-12-17       Impact factor: 3.067

View more
  11 in total

Review 1.  Zinc and gastrointestinal disease.

Authors:  Sonja Skrovanek; Katherine DiGuilio; Robert Bailey; William Huntington; Ryan Urbas; Barani Mayilvaganan; Giancarlo Mercogliano; James M Mullin
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

Review 2.  Irritable bowel syndrome.

Authors:  Paul Enck; Qasim Aziz; Giovanni Barbara; Adam D Farmer; Shin Fukudo; Emeran A Mayer; Beate Niesler; Eamonn M M Quigley; Mirjana Rajilić-Stojanović; Michael Schemann; Juliane Schwille-Kiuntke; Magnus Simren; Stephan Zipfel; Robin C Spiller
Journal:  Nat Rev Dis Primers       Date:  2016-03-24       Impact factor: 52.329

3.  Aetiological characteristics of adult acute diarrhoea in a general hospital of Shanghai.

Authors:  X Zhao; B Ni; Y Wang; X Shen; C Zhang; J Liu; S Li
Journal:  Epidemiol Infect       Date:  2016-11-03       Impact factor: 4.434

Review 4.  Management of children with prolonged diarrhea.

Authors:  Antonietta Giannattasio; Alfredo Guarino; Andrea Lo Vecchio
Journal:  F1000Res       Date:  2016-02-23

5.  Evaluation of Gelatin Tannate Against Symptoms of Acute Diarrhea in Pediatric Patients.

Authors:  Eren Çağan; Saime Ceylan; Şenay Mengi; Havva Hasret Çağan
Journal:  Med Sci Monit       Date:  2017-04-27

Review 6.  New insights into irritable bowel syndrome: from pathophysiology to treatment.

Authors:  Alexandros Hadjivasilis; Constantinos Tsioutis; Adamantios Michalinos; Dimitrios Ntourakis; Dimitrios K Christodoulou; Aris P Agouridis
Journal:  Ann Gastroenterol       Date:  2019-10-22

7.  Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.

Authors:  Kai-Cai Liu; Ying-Hong Hao; Wei-Fu Lv; Wei-Dong Jia; Chu-Shu Ji; Chun-Ze Zhou; De-Lei Cheng; Shao-Bao Xu; Zong-Gen Gao; Ming-Xue Su; Chang-Sheng Shi
Journal:  Drug Des Devel Ther       Date:  2020-08-25       Impact factor: 4.162

8.  Tannins extract from Galla Chinensis can protect mice from infection by Enterotoxigenic Escherichia coli O101.

Authors:  Xu Song; Yi Yang; Junzhi Li; Mengxue He; Yuanfeng Zou; Renyong Jia; Lixia Li; Juan Hang; Min Cui; Lu Bai; Zhongqiong Yin
Journal:  BMC Complement Med Ther       Date:  2021-03-06

9.  Xyloglucan for the Treatment of Acute Gastroenteritis in Children: Results of a Randomized, Controlled, Clinical Trial.

Authors:  Cătălin Pleșea Condratovici; Vladimir Bacarea; Núria Piqué
Journal:  Gastroenterol Res Pract       Date:  2016-05-03       Impact factor: 2.260

10.  Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion.

Authors:  Raffaella Campana; Saskia van Hemert; Wally Baffone
Journal:  Gut Pathog       Date:  2017-03-06       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.